Ligand Pharmaceuticals Incorporated
NASDAQ:LGNDBiotechnology
+$2.89 today
- Market cap
- $5.98B
- Beta
- 1.04
- P/E (TTM)
- 34.4
- EPS (TTM)
- $7.72
Volume 0.38M
Average 0.22M
LGND Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ligand Pharmaceuticals IncorporatedNASDAQ: LGND
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation outflow grows to $13.65M
Q2 FY2026 stock-based compensation was $13.65M, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $53.27M.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 24.6 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $13.65M or moves back toward the trailing-twelve-month quarterly average of $13.32M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 41.09M | +59.6% |
| FY2023 | 2023-12-31 | 25.74M | -57.3% |
| FY2022 | 2022-12-31 | 60.29M | +55.4% |
| FY2021 | 2021-12-31 | 38.78M | — |
Stock-Based Compensation vs competitors
How LGND compares with its peers on the latest reported figures
- LGND's LTM Jun 2026 stock-based compensation of $53.27M is the 9th largest of the 10 companies compared; the peer median is $187.88M.
- Its year-over-year change of +57.8% is the highest of 9, against a peer median of +4.4%.
- Stock-based compensation amounts to 18.3% of revenue for LGND, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $976M | +4.5% | +12.5% | 1.5% | |
| LTM Jun 2026 | $947M | +14.9% | -2.9% | 1.5% | |
| LTM Jun 2026 | $553M | +4.3% | +6.6% | 1.1% | |
| LTM Jun 2026 | $492M | -3.9% | +7.2% | 1.3% | |
| LTM Jun 2026 | $187.88M | -31.7% | +9.8% | 3.2% | |
| LTM Jun 2026 | $121.89M | +50.0% | +23.9% | 13.0% | |
| LTM Jul 2026 | $112.6M | +1.1% | +1.6% | 4.6% | |
| LTM Jun 2026 | $71M | — | — | 1.7% | |
| LTM Jun 2026 | $53.27M | +57.8% | — | 18.3% | |
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| Peer median (excluding LGND) | $187.88M | +4.4% | +6.9% | 1.7% | |
Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 57.14M | (33.36M) | 52.15M | (4.03M) | 124.45M |
| Depreciation & Amortization | 50.95M | 43.39M | 36.52M | 35.24M | 33.78M |
| Deferred Income Tax | (8.62M) | 20.72M | 11.7M | (15.8M) | 22.68M |
| Stock-Based Compensation | 38.78M | 60.29M | 25.74M | 41.09M | 0 |
| Change in Working Capital | (52.16M) | 65.68M | (34.4M) | 19.36M | (12.67M) |
| Accounts Receivables | (28.62M) | 55.32M | (2.6M) | (6.46M) | (21.74M) |
| Inventory | (427K) | 12.06M | (10.87M) | 9.62M | 4.99M |
| Accounts Payables | (1.17M) | (3.34M) | (4.7M) | 0 | 5.88M |
| Other Working Capital | (21.96M) | 1.64M | (16.23M) | 16.2M | (1.8M) |
| Other Non-Cash Items | (7.29M) | (18.87M) | (42.14M) | 21.2M | (118.89M) |
| Operating Cash Flow | 78.8M | 137.85M | 49.58M | 97.05M | 49.36M |
| Capital Expenditures | (8.76M) | (17.92M) | (53.85M) | (19.64M) | (452K) |
| Acquisitions (Net) | 494K | (750K) | (25.65M) | (172.19M) | (8.09M) |
| Purchases of Investments | (181.33M) | (51.23M) | (126.76M) | (226.38M) | (730.86M) |
| Sales of Investments | 221.34M | 234.39M | 194.17M | 269.62M | 377.28M |
| Other Investing Activities | (1.22M) | (868K) | (49.91M) | (12.89M) | (4.34M) |
| Investing Cash Flow | 30.52M | 163.62M | (11.68M) | (143.66M) | (377.32M) |
| Debt Repayment | (146.01M) | (260.8M) | (76.9M) | (25K) | 338.11M |
| Common Stock Issued | 33.76M | 3.23M | 22.45M | 37.14M | 114.89M |
| Common Stock Repurchased | (18.45M) | 0 | 0 | 0 | (15M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.07M) | (18.42M) | (5.5M) | 60.03M | (9.77M) |
| Financing Cash Flow | (137.76M) | (275.99M) | (59.95M) | 97.14M | 428.22M |
| Effect of Forex Changes | 0 | 0 | 0 | (1.17M) | 2.36M |
| Net Change in Cash | (28.44M) | 25.48M | (22.05M) | 49.35M | 102.62M |
| Free Cash Flow | 70.04M | 119.93M | (4.27M) | 77.41M | 48.91M |
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Intrinsic Alpha fair value
Locked
Current Price
$298.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.